Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things that we can do to reduce kidney injury. However, (unfortunately) sodium bicarbonate showed no benefit over saline and n-acetylcysteine showed no benefit over a placebo for the reduction of kidney damage after coronary angioplasty.

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónicaAmong the protective measures most frequently tested are endovenous sodium bicarbonate and oral n-acetylcysteine, both with conflicting results.

 

The PRESERVE (Prevention of Serious Adverse Events Following Angiography) trial used a 2 × 2 factorial design and randomized 5177 patients with stage III or IV renal insufficiency requiring angiography to 1.26% sodium bicarbonate or 0.9% sodium chloride and n-acetylcysteine or placebo for 5 days. The primary endpoint was a composite of death, need for dialysis, or persistent renal insufficiency at 90 days. Contrast-associated acute kidney injury was a secondary endpoint.


Read also: Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions.


A total of 1161 study patients underwent coronary angioplasty. The mean glomerular filtration rate was 50.7 mL/min/1.73 m2 and 82% of the population had a history of diabetes.

 

The primary endpoint occurred in 2.6% of patients who received sodium bicarbonate vs. 4% of patients who received saline (p = 0.41) and in 3.8% of patients who received n-acetylcysteine vs. 2.8% of patients who received a placebo (p = 0.29). There were no significant differences among groups as regards the incidence of contrast-associated kidney injury.

 

Conclusion

Among patients with chronic kidney disease who underwent angioplasty, there was no benefit of sodium bicarbonate over regular saline or of n-acetylcysteine over placebo for the prevention of contrast-associated kidney injury.

 

Original title: Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. A Subgroup Analysis of the PRESERVE Trial.

Reference: Santiago Garcia et al. J Am Coll Cardiol Intv 2018;11:2254-61.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...